These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 23229603

  • 1. [Primary prevention of diabetic nephropathy].
    Trevisan R.
    G Ital Nefrol; 2012; 29 Suppl 58():S49-53. PubMed ID: 23229603
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 3. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Nov; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 4. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases].
    Esnault V.
    Nephrol Ther; 2006 May; 2 Suppl 3():S193-6. PubMed ID: 17370850
    [Abstract] [Full Text] [Related]

  • 5. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D.
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [Abstract] [Full Text] [Related]

  • 6. Preventing end-stage renal disease.
    Mogensen CE.
    Diabet Med; 1998 Mar; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [Abstract] [Full Text] [Related]

  • 7. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.
    McKenna K, Thompson C.
    Scott Med J; 1997 Aug; 42(4):99-104. PubMed ID: 9507584
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin converting enzyme inhibitors in diabetic patients with microalbuminuria or normoalbuminuria.
    Viberti G, Chaturvedi N.
    Kidney Int Suppl; 1997 Dec; 63():S32-5. PubMed ID: 9407417
    [Abstract] [Full Text] [Related]

  • 9. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
    Donnelly R, Yeung JM, Manning G.
    J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161
    [Abstract] [Full Text] [Related]

  • 10. [Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
    Feldt-Rasmussen BF.
    Ugeskr Laeger; 2002 Apr 01; 164(14):1907-9. PubMed ID: 11957423
    [No Abstract] [Full Text] [Related]

  • 11. [Is microalbuminuria, an early marker of clinical nephropathy, also a cardiovascular risk factor?].
    Raynaud E, Brun JF, Fédou C, Puech-Cathala AM, Pérez-Martin A, Orsetti A.
    Ann Biol Clin (Paris); 1998 Apr 01; 56(6):671-9. PubMed ID: 9853026
    [Abstract] [Full Text] [Related]

  • 12. [Prediction, screening and treatment of renal complications of diabetes].
    Marre M, Larger E.
    Rev Prat; 2001 Oct 15; 51(16):1769-75. PubMed ID: 11795120
    [Abstract] [Full Text] [Related]

  • 13. Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review.
    Persson F, Lindhardt M, Rossing P, Parving HH.
    J Renin Angiotensin Aldosterone Syst; 2016 Jul 15; 17(3):. PubMed ID: 27488274
    [Abstract] [Full Text] [Related]

  • 14. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M, Deferrari L, Ratto E, Vettoretti S, Parodi D, Deferrari G.
    Ital Heart J Suppl; 2003 Mar 15; 4(3):210-6. PubMed ID: 12784755
    [Abstract] [Full Text] [Related]

  • 15. Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?
    Kiberd BA, Jindal KK.
    Mayo Clin Proc; 1999 Jun 15; 74(6):559-64. PubMed ID: 10377929
    [Abstract] [Full Text] [Related]

  • 16. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
    Parving HH, Hovind P.
    Curr Hypertens Rep; 2002 Oct 15; 4(5):387-93. PubMed ID: 12217258
    [Abstract] [Full Text] [Related]

  • 17. Effects of ACE inhibition on the course of nephropathy in type I diabetes mellitus.
    Meinders AE, Hes R, de Leeuw PW.
    Neth J Med; 1992 Jun 15; 40(5-6):217-20. PubMed ID: 1436257
    [Abstract] [Full Text] [Related]

  • 18. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME.
    J Hypertens Suppl; 1996 Dec 15; 14(6):S11-4. PubMed ID: 9023709
    [Abstract] [Full Text] [Related]

  • 19. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes.
    Mogensen CE.
    J Intern Med; 2003 Jul 15; 254(1):45-66. PubMed ID: 12823642
    [Abstract] [Full Text] [Related]

  • 20. [Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy].
    Philips JC, Weekers L, Scheen AJ.
    Rev Med Liege; 2001 Feb 15; 56(2):126-8. PubMed ID: 11294048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.